Analyst Price Target is $31.50
▲ +301.27% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for iTeos Therapeutics in the last 3 months. The average price target is $31.50, with a high forecast of $46.00 and a low forecast of $24.00. The average price target represents a 301.27% upside from the last price of $7.85.
Current Consensus is
Buy
The current consensus among 4 polled investment analysts is to buy stock in iTeos Therapeutics.
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Read More
